Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
FIGURE: 1 / 2
Bevacizumab Antibody (A01977-40) in ELISA
Standard curve of Beacizumab Sandwich ELISA. The Beacizumab Sandwich ELISA assay is developed by using Anti-Beacizumab Antibody (4H1), mAb, Mouse (GenScript, A01975-40) and Anti-Beacizumab Antibody (6C3) [Biotin] (GenScript, A01977-40) as the capture and detection antibodies, respectivelyThe Sensitivity is less than 78 pg/mL.
Product Details
A01977-40
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1
Class
Monoclonal
Type
Antibody
Clone
6C3
Immunogen
Bevacizumab
Conjugate
Form
Lyophilized
Purification
Protein A
Storage buffer
PBS, pH 7.4, with 1% BSA
Contains
0.02% sodium azide
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of a number of types of cancers and a specific eye disease. Bevacizumab binds a continuous epitope in VEGF, preventing interaction of VEGF with VEGFR on the surface of endothelial cells. It can be used to inhibit solid tumour growth and metastasis by weakening tumour angiogenesis.Anti-Bevacizumab Antibody (6C3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Bevacizumab.
Target Information
Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support